Optibrium, a software and artificial intelligence (AI) solutions developer for drug discovery, has announced three appointments: Michelle Harrison as Head of Strategic Marketing, Chris Khoury as Associate Director of Business Development, and Imran Ghauri as Business Development Manager.
The company says the appointments will bring extensive AI and life science expertise and will align global business development and marketing strategies to further develop and commercialise Optibrium’s computer-aided drug discovery technologies.
More than 170 organisations worldwide, including five of the top 10 global pharmaceutical companies, currently deploy Optibrium’s computational drug discovery technologies in their research programmes. Cerella, Optibrium’s proven AI platform, empowers project teams with valuable insights from complex drug discovery data to maximise the success of preclinical discovery projects.
Dr Matthew Segall, CEO of Optibrium, said: “As part of our continuing expansion and commercial success, we are delighted to welcome Michelle, Chris and Imran to the Optibrium team. Their impressive backgrounds in scientific marketing strategy and business development will power the next phase of our development and further strengthen the position of our market-leading in silico technologies and AI platforms.”
